Compare Equinix Inc (EQIX) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance

Equinix (EQIX) trades at $1,016.30, down 1.5% on the day, amid a bullish technical trend and strong analyst support. The stock shows robust revenue growth, with 2025 revenue reaching $9.22 billion and net income margin improving to 14.64%. Recent news highlights accelerating AI-driven demand for data centers, with the company planning $5–7 billion in annual investments. However, high valuation ratios like a P/E of 65.07 and negative net cash flow in 2025 pose concerns.

The outlook for EQIX is positive due to AI infrastructure demand and solid earnings growth, but risks include elevated debt levels and capital expenditure pressures. Wall Street consensus is strongly bullish with a $1,250 price target, though investors should weigh valuation against execution risks in a competitive sector.

DENTSPLY SIRONA (XRAY) trades at $8.54, near its 52-week low, with bearish technical indicators and mixed fundamentals. The company reported Q2 2026 EPS of $0.52 beating expectations but revenue declined 4.1% year-over-year. Net income remains negative at -$598 million for 2025, though margins show slight improvement. Analyst consensus is mixed with 37.5% buy ratings but a $13.40 price target suggesting 57% upside potential from current levels.

The stock presents a high-risk turnaround opportunity with significant upside if management's restructuring efforts succeed, but faces headwinds from declining sales, margin pressure, and competitive challenges in dental markets. Institutional ownership changes and ongoing transformation investments create both uncertainty and potential for recovery.